"We will continue to focus on a range of issues in relation to the PBS, of course, and important internal matters like governance, the Code of Conduct and listening to the membership - but our industry is also on the cusp of something quite extraordinary," says Vifor Pharma's James McDonnell.
James McDonnell: Industry 'on the cusp of something quite extraordinary'
September 20, 2019 Latest NewsBioPharmaDispatch Executive
Latest Video
New Stories
-
The 'Dispatched' Podcast - Week in review
August 7, 2026 - - Podcast -
argenx partners with Monash University and Myostellar to develop muscular therapies
August 7, 2026 - - Latest News -
A new generation is rewriting their lives living with Cystic Fibrosis
August 7, 2026 - - Latest News -
US approves Moderna's mRNA flu vaccine in major technology milestone
August 7, 2026 - - Latest News -
If Australian companies shun their domestic market, who can blame multinationals?
August 6, 2026 - - Latest News -
Neuren reports record DAYBUE sales as royalties rise and global expansion nears
August 6, 2026 - - Australian Biotech -
Moderna begins Phase 1 trial of vaccine candidate against Bundibugyo Ebola Virus
August 6, 2026 - - Latest News

